Dental Intelligence vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 52)
Dental Intelligence logo

Dental Intelligence

ChallengerHealthtech

Dental Practice Analytics

Practice analytics and patient engagement platform for dental offices helping DSOs and independents grow production. American Fork UT; founded 2016; connects to 100+ dental PMS systems;

AI VisibilityBeta
Overall Score
C52
Category Rank
#281 of 596
AI Consensus
88%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
53
Gemini
50

About

Dental Intelligence is an American Fork, Utah-based dental practice analytics and patient engagement platform that helps dental offices, group practices, and dental support organizations (DSOs) analyze production data, identify growth opportunities, and improve patient engagement and retention. Founded in 2016, the company built its platform around a core insight: most dental practices generate enormous amounts of operational data in their practice management software but lack the tools to turn that data into actionable insights. Dental Intelligence connects to over 100 dental practice management systems—including Dentrix, Eaglesoft, OpenDental, and Carestream—and automatically analyzes key performance indicators including production per provider, case acceptance rates, recall effectiveness, hygiene reappointment rates, and collections performance.\n\nThe platform's patient engagement tools allow dental practices to automate appointment reminders, recall outreach, and reactivation campaigns for patients who are overdue for cleanings or who have unscheduled treatment plans. These engagement automations reduce the manual administrative burden on front desk staff while improving patient show rates and reducing last-minute cancellations that disrupt production schedules. Dental Intelligence's analytics layer surfaces the specific operational levers most likely to drive revenue growth for each practice—whether that is improving treatment plan acceptance, filling hygiene chairs more efficiently, or reducing same-day cancellations.\n\nDental Intelligence has found particular traction with multi-location DSO customers that need consistent performance analytics and benchmarking across dozens or hundreds of dental practices. The platform's DSO-tier dashboards allow regional managers and corporate leadership to compare location performance, identify underperforming practices, and replicate the operational practices of top performers. The company competes with Weave, Solutionreach, and Carestream Dental in the dental technology market, differentiating on the depth of its practice analytics and its broad integration with existing dental practice management systems.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

52
Overall Score
81
#281
Category Rank
#17
88
AI Consensus
71
stable
Trend
stable
52
ChatGPT
80
53
Perplexity
75
50
Gemini
77
48
Claude
86
52
Grok
85

Key Details

Category
Dental Practice Analytics
General
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Dental Intelligence
Dental Practice Analytics

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.